The vaccine, called Ervebo, protects against Zaire ebolavirus, the species of viruses that most commonly causes Ebola outbreaks, according to STAT. It is the virus responsible for the current long-running outbreak in the Democratic Republic of the Congo.
Ervebo will likely be stockpiled by countries, including the U.S., as a guard against a possible bioterrorism attack, according to STAT.
It is a single-dose vaccine that generates a quick immune response, with protection against the virus occurring within about 10 days and is approved for people 18 years or older.
The FDA approval follows the European Commission licensing the vaccine on Nov. 11, according to STAT.
Read the full article here.
More articles on pharmacy:
Novartis plans giveaway of world’s most expensive drug
Albertsons launches 1- to 2-hour prescription deliveries
Smart Pharmacy lays off most of workforce
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.